A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 12, 2026 115 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR New Device Could “Hear” Stiffening of Extracellular Matrix to Determine Where... April 2, 2020 Pan-FGFR Tyrosine Kinase Inhibitor Treatment Is Less Effective in Patients with... March 2, 2021 Using Integrative Therapies to Help Manage Cancer-Related Pain: An Expert Q&A July 20, 2023 How we can reduce cancer risk in inflammatory bowel disease patients... August 23, 2022 Load more HOT NEWS Evaluation of Pemigatinib Efficacy in FGFR-Altered Advanced Solid Tumours Led to... Combination of Azacitidine and Venetoclax in Previously Untreated AML Can AI Help Predict Which Cancer Patients Should Be Treated with... Novel Checklist for Quality of Life to Bring ESMO-MCBS and Clinical...
